October 22, 2026, 07:00 am CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases ...
There is a growing risk within the French residential development end-market for 2027—a view shared by management. In recent years, the company has positioned itself to address this emerging risk. Q3 ...
Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results